BioCardia, Inc. (NASDAQ:BCDA) Short Interest Down 39.6% in December

BioCardia, Inc. (NASDAQ:BCDA) was the target of a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 50,400 shares, a drop of 39.6% from the December 15th total of 83,400 shares. Approximately 1.3% of the company’s shares are short sold. Based on an average daily volume of 48,500 shares, the days-to-cover ratio is presently 1.0 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of BioCardia in a report on Wednesday, December 18th.

BioCardia Trading Down 1.5 %

Shares of BioCardia stock traded down $0.03 on Thursday, hitting $2.18. 18,532 shares of the company traded hands, compared to its average volume of 37,543. The company has a market cap of $9.97 million, a PE ratio of -0.52 and a beta of 1.26. The stock’s 50 day moving average price is $2.19 and its 200-day moving average price is $2.58. BioCardia has a 52 week low of $1.63 and a 52 week high of $9.42.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.